Wegovy Price in India: A New Era for Novo Nordisk's Weight-Loss Drug

Wegovy Price in India: Expected Launch Details

Danish pharma giant Novo Nordisk is preparing to launch blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. To gain an edge over Eli Lilly's Mounjaro, which was recently introduced, Novo Nordisk emphasizes the cardiovascular benefits of Wegovy in Indian patients. Wegovy is expected to be launched in a few months at a competitive price level, as industry experts note that Novo Nordisk has limited time to respond to Mounjaro's positive traction.

Regulatory Approval and Usage

• The drug has received approval regarding its cardiovascular risk reduction claims from India's Expert Committee under the central drug authority.
• Wegovy can be prescribed by both endocrinologists, internal medicine specialists, and cardiologists.
• If approved by the Drug Controller General of India, Wegovy will be a new treatment avenue for individuals facing diabetes and heart disease.

Market Impact

The approval for Wegovy expands its label, providing Novo Nordisk a competitive advantage in the growing obesity drug market. However, expert opinions suggest that the cost of Wegovy will play a pivotal role in its overall success.

Nishith Chandra, from Fortis Escorts Heart Institute, states that unless pharmaceutical companies can offer these designer medicines at lower prices, they will likely remain accessible only to a limited patient population.

Despite previously securing approvals for diabetes and weight-loss treatment, Wegovy's launch has been delayed due to global demand issues. Meanwhile, Novo Nordisk's oral drug Rybelsus was introduced in 2022, though it has lesser efficacy compared to injections.